International Clinical Trial: A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac Echocardiography

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07740421) titled 'A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac Echocardiography' on July 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).

Primary Sponsor: Trust Bio-sonics, Inc.

Condition: Cardiac Diseases

Intervention: Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enr...